FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2493739004> ?p ?o ?g. }

• W2493739004 endingPage "16" @default.
• W2493739004 startingPage "209" @default.
• W2493739004 abstract "Canine hemangiosarcoma (HSA) is a progressive malignant neoplasm with no current effective treatment. Previous studies showed that receptor tyrosine kinases and molecules within their downstream pathways involving phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (m-TOR) or mitogen-activated protein kinase (MAPK) were overexpressed in canine, human, and murine tumors, including HSA. The present study investigated the effects of inhibitors of these pathways in canine splenic and hepatic HSA cell lines using assays of cell viability and apoptosis. Inhibitors of the MAPK pathway did not affect canine HSA cell viability. However, cell viability was significantly reduced by exposure to inhibitors of vascular endothelial growth factor receptor 2 and the PI3K/Akt/m-TOR pathway; these inhibitors also induced apoptosis in these cell lines. These results suggest that these inhibitors reduce the proliferation of canine HSA cells by inducing apoptosis. Further study of these inhibitors, using xenograft mouse models of canine HSA, are warranted to explore their potential for clinical application. L’hémangiosarcome canin (HS) est un néoplasme malin progressif sans traitement efficace actuel. Des études antérieures ont montré que les récepteurs à activité tyrosine kinase et les molécules dans la voie en aval impliquant la phospatidylinositol 3-kinase (PI3K)/Akt/cible mammalienne de rapamycine (m-TOR) ou la protéine kinase activée par mitogène (PKAM) étaient surexprimées dans les tumeurs canine, humaine, et murine, incluant HS. La présente étude visait à examiner les effets d’inhibiteurs de ces voies dans des lignées cellulaires spléniques et hépatiques de HS en utilisant des essais de viabilité cellulaire et d’apoptose. Les inhibiteurs de la voie PKAM n’ont pas affecté la viabilité de cellules d’HS canines. Toutefois, la viabilité cellulaire était réduite de manière significative suite à l’exposition à des inhibiteurs des récepteurs 2 du facteur de croissance de l’endothélium vasculaire et de la voie PI3K/Akt/m-TOR; ces inhibiteurs ont également induit l’apoptose dans ces lignées cellulaires. Ces résultats suggèrent que ces inhibiteurs réduisent la prolifération de cellules HS canines en induisant l’apoptose. Des études additionnelles de ces inhibiteurs, à l’aide de modèles murins de xénogreffes de HS canins, sont requises afin d’explorer leur potentiel pour une application clinique.(Traduit par Docteur Serge Messier)." @default.
• W2493739004 created "2016-08-23" @default.
• W2493739004 creator A5013245766 @default.
• W2493739004 creator A5021427559 @default.
• W2493739004 creator A5028104790 @default.
• W2493739004 creator A5032033847 @default.
• W2493739004 creator A5040341588 @default.
• W2493739004 date "2016-07-01" @default.
• W2493739004 modified "2023-09-23" @default.
• W2493739004 title "Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines." @default.
• W2493739004 cites W1506923787 @default.
• W2493739004 cites W1533802152 @default.
• W2493739004 cites W1560608058 @default.
• W2493739004 cites W1593875197 @default.
• W2493739004 cites W1752845679 @default.
• W2493739004 cites W1920173756 @default.
• W2493739004 cites W1970244138 @default.
• W2493739004 cites W1971451473 @default.
• W2493739004 cites W1979724799 @default.
• W2493739004 cites W1980177367 @default.
• W2493739004 cites W2013811004 @default.
• W2493739004 cites W2014135835 @default.
• W2493739004 cites W2020535613 @default.
• W2493739004 cites W2025589818 @default.
• W2493739004 cites W2032279528 @default.
• W2493739004 cites W2039004811 @default.
• W2493739004 cites W2074544404 @default.
• W2493739004 cites W2089756110 @default.
• W2493739004 cites W2089955307 @default.
• W2493739004 cites W2094484532 @default.
• W2493739004 cites W2101350187 @default.
• W2493739004 cites W2103689840 @default.
• W2493739004 cites W2106478689 @default.
• W2493739004 cites W2115590950 @default.
• W2493739004 cites W2116672406 @default.
• W2493739004 cites W2120077550 @default.
• W2493739004 cites W2120203403 @default.
• W2493739004 cites W2124255159 @default.
• W2493739004 cites W2126372596 @default.
• W2493739004 cites W2127278176 @default.
• W2493739004 cites W2146488945 @default.
• W2493739004 cites W2147402939 @default.
• W2493739004 cites W2164655047 @default.
• W2493739004 cites W2179410198 @default.
• W2493739004 cites W2265845847 @default.
• W2493739004 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4924555" @default.
• W2493739004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27408334" @default.
• W2493739004 hasPublicationYear "2016" @default.
• W2493739004 type Work @default.
• W2493739004 sameAs 2493739004 @default.
• W2493739004 citedByCount "6" @default.
• W2493739004 countsByYear W24937390042017 @default.
• W2493739004 countsByYear W24937390042018 @default.
• W2493739004 countsByYear W24937390042019 @default.
• W2493739004 countsByYear W24937390042022 @default.
• W2493739004 countsByYear W24937390042023 @default.
• W2493739004 crossrefType "journal-article" @default.
• W2493739004 hasAuthorship W2493739004A5013245766 @default.
• W2493739004 hasAuthorship W2493739004A5021427559 @default.
• W2493739004 hasAuthorship W2493739004A5028104790 @default.
• W2493739004 hasAuthorship W2493739004A5032033847 @default.
• W2493739004 hasAuthorship W2493739004A5040341588 @default.
• W2493739004 hasConcept C101544691 @default.
• W2493739004 hasConcept C153911025 @default.
• W2493739004 hasConcept C184235292 @default.
• W2493739004 hasConcept C185592680 @default.
• W2493739004 hasConcept C2780610907 @default.
• W2493739004 hasConcept C42362537 @default.
• W2493739004 hasConcept C502942594 @default.
• W2493739004 hasConcept C55493867 @default.
• W2493739004 hasConcept C57074206 @default.
• W2493739004 hasConcept C62112901 @default.
• W2493739004 hasConcept C62478195 @default.
• W2493739004 hasConcept C75217442 @default.
• W2493739004 hasConcept C86554907 @default.
• W2493739004 hasConcept C86803240 @default.
• W2493739004 hasConcept C95444343 @default.
• W2493739004 hasConceptScore W2493739004C101544691 @default.
• W2493739004 hasConceptScore W2493739004C153911025 @default.
• W2493739004 hasConceptScore W2493739004C184235292 @default.
• W2493739004 hasConceptScore W2493739004C185592680 @default.
• W2493739004 hasConceptScore W2493739004C2780610907 @default.
• W2493739004 hasConceptScore W2493739004C42362537 @default.
• W2493739004 hasConceptScore W2493739004C502942594 @default.
• W2493739004 hasConceptScore W2493739004C55493867 @default.
• W2493739004 hasConceptScore W2493739004C57074206 @default.
• W2493739004 hasConceptScore W2493739004C62112901 @default.
• W2493739004 hasConceptScore W2493739004C62478195 @default.
• W2493739004 hasConceptScore W2493739004C75217442 @default.
• W2493739004 hasConceptScore W2493739004C86554907 @default.
• W2493739004 hasConceptScore W2493739004C86803240 @default.
• W2493739004 hasConceptScore W2493739004C95444343 @default.
• W2493739004 hasIssue "3" @default.
• W2493739004 hasLocation W24937390041 @default.
• W2493739004 hasOpenAccess W2493739004 @default.
• W2493739004 hasPrimaryLocation W24937390041 @default.
• W2493739004 hasRelatedWork W1561643266 @default.
• W2493739004 hasRelatedWork W2024936926 @default.

• next